Merck & Co., Inc.
MRK
Rangering i aksjer
#38
Merck & Co., Inc. is a global healthcare leader with operations spanning two... Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
Aksjekurs
$148.13
Markedsverdi
$365.46B
Endring (1 dag)
3.15%
Endring (1 år)
71.61%
Land
US
Handel Merck & Co., Inc. (MRK)
Kategori
Healthcare
Inntekter for Merck & Co., Inc. (MRK)
Inntekter i Jun 2026 TTM: $5.95B
Ifølge Merck & Co., Inc. sine nyeste økonomiske rapporter er selskapets nåværende resultat $5.95B. I 2024 hadde selskapet et resultat på $19.94B, en økning sammenlignet med resultatet i 2023, som var $1.89B. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for Merck & Co., Inc. fra 2000 til 2026
Inntekter ved slutten av hvert år
| År | Inntekter | Endre |
|---|---|---|
| 2026 (TTM) | $5.95B | -71.77% |
| 2025 | $21.07B | 5.67% |
| 2024 | $19.94B | 955.37% |
| 2023 | $1.89B | -88.51% |
| 2022 | $16.44B | 18.48% |
| 2021 | $13.88B | 136.72% |
| 2020 | $5.86B | -18.24% |
| 2019 | $7.17B | -17.58% |
| 2018 | $8.70B | 33.43% |
| 2017 | $6.52B | 39.97% |
| 2016 | $4.66B | -13.74% |
| 2015 | $5.40B | -68.75% |
| 2014 | $17.28B | 211.69% |
| 2013 | $5.55B | -36.55% |
| 2012 | $8.74B | 19.16% |
| 2011 | $7.33B | 343.68% |
| 2010 | $1.65B | -89.19% |
| 2009 | $15.29B | 53.96% |
| 2008 | $9.93B | 194.63% |
| 2007 | $3.37B | -45.82% |
| 2006 | $6.22B | -15.51% |
| 2005 | $7.36B | -7.98% |
| 2004 | $8.00B | -11.59% |
| 2003 | $9.05B | -6.22% |
| 2002 | $9.65B | -2.98% |
| 2001 | $9.95B | 1.26% |
| 2000 | $9.82B | 0.00% |
Inntekter for lignende selskaper eller konkurrenter
| Selskap | Inntekter | Forskjell i inntekter | Land |
|---|---|---|---|
| $33.60B | 464.82% |
US
|
|
| $17.74B | 198.20% |
US
|
|
| $8.70B | 46.25% |
US
|
|
| $21.39B | 259.59% |
CH
|
|
| $16.38B | 175.36% |
CH
|
